Literature DB >> 2610508

Pharmacokinetics of amphotericin B in children.

J M Benson1, M C Nahata.   

Abstract

Amphotericin B is the most effective agent for the majority of systemic fungal infections but often causes toxicity, and specific dosage guidelines for amphotericin B in pediatric patients are lacking. The purpose of this study was to characterize the pharmacokinetics of amphotericin B in children. Twelve patients (mean age, 6.6 years; range, 4 months to 14 years) receiving amphotericin B, 0.68 +/- 0.34 mg/kg per day (mean plus or minus standard deviation), were studied. Four to eight blood samples were collected during a 24-h period and analyzed by high-pressure liquid chromatography. The peak concentration of amphotericin B in serum was 2.9 +/- 2.8 micrograms/ml. The mean total clearance, apparent volume of distribution, and elimination half-life were 0.46 +/- 0.20 ml/min per kg, 0.76 +/- 0.52 liters/kg, and 18.1 +/- 6.6 h, respectively. Total clearance decreased with age (p less than 0.01). In children aged 8 months to 9 years, the mean total clearance was 0.57 +/- 0.15 ml/min per kg, and in children older than 9 years, it was 0.24 +/- 0.02 ml/min per kg. Interpatient variation in the clearance and volume of distribution of amphotericin B was greater than threefold and greater than eightfold, respectively. However, pharmacokinetic parameters did not change in two stable patients who were studied again. Because clearance decreased substantially with age, older children may require lower doses of amphotericin B per kilogram to decrease the potential for toxicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2610508      PMCID: PMC172800          DOI: 10.1128/AAC.33.11.1989

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Amphotericin B dosage for disseminated candidiasis in premature infants.

Authors:  J E Hall; F Cox; K Karlson; A Robertson
Journal:  J Perinatol       Date:  1987       Impact factor: 2.521

Review 2.  Clinical use of systemic antifungal agents.

Authors:  J M Benson; M C Nahata
Journal:  Clin Pharm       Date:  1988-06

3.  Amphotericin B pharmacokinetics in humans.

Authors:  A J Atkinson; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

4.  Pharmacokinetics of amphotericin B in infants and children.

Authors:  J R Starke; E O Mason; W G Kramer; S L Kaplan
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

5.  Pharmacokinetics and adverse effects of amphotericin B in infants and children.

Authors:  G Koren; A Lau; J Klein; C Golas; M Bologa-Campeanu; S Soldin; S M MacLeod; C Prober
Journal:  J Pediatr       Date:  1988-09       Impact factor: 4.406

6.  Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients.

Authors:  V Fainstein; G P Bodey; L Elting; A Maksymiuk; M Keating; K B McCredie
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

7.  Sensitive high-pressure liquid chromatographic assay for amphotericin B which incorporates an internal standard.

Authors:  G G Granich; G S Kobayashi; D J Krogstad
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

  7 in total
  27 in total

Review 1.  Pharmacokinetics of antifungal agents in children.

Authors:  Kevin Watt; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Early Hum Dev       Date:  2011-02-01       Impact factor: 2.079

2.  Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers.

Authors:  S W Sanders; K N Buchi; M S Goddard; J K Lang; K G Tolman
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

3.  Possible reason for preferential damage to renal tubular epithelial cells evoked by amphotericin B.

Authors:  I Walev; S Bhakdi
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factor.

Authors:  Iftekhar Mahmood
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

5.  Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.

Authors:  T J Walsh; P Whitcomb; S Piscitelli; W D Figg; S Hill; S J Chanock; P Jarosinski; R Gupta; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

Review 6.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

7.  Population pharmacokinetics of amphotericin B in children with malignant diseases.

Authors:  C E Nath; A J McLachlan; P J Shaw; R Gunning; J W Earl
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

8.  Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling.

Authors:  G Robbie; W L Chiou
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

9.  Flow cytometric assay for estimating fungicidal activity of amphotericin B in human serum.

Authors:  E Martin; U Schlasius; S Bhakdi
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

10.  Novel aspect of amphotericin B action: accumulation in human monocytes potentiates killing of phagocytosed Candida albicans.

Authors:  E Martin; A Stüben; A Görz; U Weller; S Bhakdi
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.